We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ImmuneRegen® BioSciences Releases Study Results Showing Homspera™ Stimulates Adult Stem Cell Activity
News

ImmuneRegen® BioSciences Releases Study Results Showing Homspera™ Stimulates Adult Stem Cell Activity

ImmuneRegen® BioSciences Releases Study Results Showing Homspera™ Stimulates Adult Stem Cell Activity
News

ImmuneRegen® BioSciences Releases Study Results Showing Homspera™ Stimulates Adult Stem Cell Activity

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ImmuneRegen® BioSciences Releases Study Results Showing Homspera™ Stimulates Adult Stem Cell Activity"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ImmuneRegen BioSciences, Inc., a wholly owned biotechnology product development and licensing subsidiary of IR BioSciences Holdings, Inc. has reported study findings on its drug candidate Homspera™.

The results show Homspera to be effective in stimulating human, adult, blood-forming stem cells (hematopoietic stem cells), which have previously been shown to be capable of becoming blood cells that are vital to the body’s immune system. This suggests a role for Homspera in strengthening the human immune system.

The study by HemoGenix, a research laboratory specializing in stem cell applications that serves the biotechnology and pharmaceutical industries, found ImmuneRegen’s Homspera not only increased the number of early-stage white blood cells by up to 200 percent when compared to controls, but also produced this effect at surprisingly low concentrations.

These findings indicate Homspera’s potential benefit in situations where regenerating or stimulating the immune system is desired, as with patients undergoing chemotherapy who may develop leukopenia (low number of white blood cells).

“These results help explain the myriad of successful animal studies previously reported for Homspera in widely diverse areas of health-related fields, including Homspera’s positive results in influenza therapy, combating the effects of radiation exposure and enhancing the efficacy of vaccines (vaccine adjuvant activity),” said ImmuneRegen Scientific Director Kasey Benson, Ph.D. “These findings from adult human stem cells suggest that Homspera could also produce positive effects clinically.”

In the study, Homspera promoted the development of early-stage white blood cells and platelet precursors when added to a cell culture of human hematopoietic stem cells. “I have never seen these stimulatory activities at such low concentrations of test compound,” said Ivan N. Rich, Ph.D., HemoGenix founder, chairman and CEO and an internationally recognized leader in hematology research.

Said Benson, “We are excited about the broad range of health-related applications Homspera promises.” ImmuneRegen plans further studies to better understand Homspera’s role in immune-system regeneration and to search for potential drug applications.

Advertisement